TY - JOUR
T1 - Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of t-lymphocyte in human bladder tumor cell s in vitro
AU - Li, Yong Gang
AU - Wang, Zhi Ping
AU - Tian, Jun Qiang
AU - Tian, Bin Qiang
AU - Rodrigues, Ronald
AU - Shang, Pan Feng
AU - Zhang, Tao
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/10/22
Y1 - 2009/10/22
N2 - Objectives: The aim of this study was to investigate whether dendritic cells (DCs) transfected with human secondary lymphoid-tissue chemokine (hSLC) and human interleukin-2 (hIL-2) genes are capable of improving DC's proliferation and to produce a marked antitumor effect in vitro combined with T-lymphocyte (TC). Methods: SLC gene primer was designed based on the corresponding gene sequence in GenBank. The Kpn I site was introduced into the upstream of the primer and Xho I site into the downstream. The SLC gene was amplified with the template of pET32a()-SLC by polymerase chain reaction. SLC was cloned into pBudCE4.1/IL-2 (TRAIL was cut from pBudCE4.1/TRAIL- IL-2 before) to construct recombinant plasmid pBudCE4.1/SLC-IL-2(PSI). DCs were transfected with pBudCE4.1/SLC-IL-2 by gene electric transfection. Protein expression was determined with Western blot and enzyme-linked immunosorbent assays. Cytotoxicity of TC and DC against the human bladder tumor cell were examined by chromium release assay. Flow cytometric analyses were performed to determine the apoptosis of tumor cells and the percentage of Treg. Results: A high level of expression of SLC and IL-2 was observed in DCs transfected with SLC and IL-2 genes. The mean production of IL-2 was 19.8 ± 2.5, 511.10 ± 52.36, and 541.3 ± 62.04 ng/106 cells/24 hours in the DC/vector, DC/IL-2, and DC/SLC-IL-2, respectively. The mean SLC production was 29.8 ± 4.43, 506.10 ± 42.36, and 567.34 ± 52.05 ngs/10 6cells/24 hours in the DC/ vector, DC/SLC, and DC/SLC-IL-2, respectively. Cytotoxicity to bladder cancer cells was increased. The mean cytotoxicity (the effector/target ratio, 40:1) of TC-DC/parental, TC-DC/IL-2, TC-DC/SLC, and TC-DC/SLC-IL-2(TDSI) to the human bladder cancer cells was 32.1 ± 5.5, 63.5 ± 6.6, 78.1 ± 9.63, respectively. The apoptotsis rate of bladder cancer cells treated with TDSI was 18.6 by flow cytometry. Treg cells' percentage was very small in the DC medium. Conclusions: SLC and IL-2 were produced by autocrine in DCs transfected with SLC and IL-2 genes. DC/SLC-IL-2 can promote DC proliferation, while TC-DC/SLC-IL-2 and TC-DC/SLC could strongly enhance significant cytotoxicity against bladder cancer cell that was induced by the coculture of DCs (transfected with SLC and IL-2) and TC.
AB - Objectives: The aim of this study was to investigate whether dendritic cells (DCs) transfected with human secondary lymphoid-tissue chemokine (hSLC) and human interleukin-2 (hIL-2) genes are capable of improving DC's proliferation and to produce a marked antitumor effect in vitro combined with T-lymphocyte (TC). Methods: SLC gene primer was designed based on the corresponding gene sequence in GenBank. The Kpn I site was introduced into the upstream of the primer and Xho I site into the downstream. The SLC gene was amplified with the template of pET32a()-SLC by polymerase chain reaction. SLC was cloned into pBudCE4.1/IL-2 (TRAIL was cut from pBudCE4.1/TRAIL- IL-2 before) to construct recombinant plasmid pBudCE4.1/SLC-IL-2(PSI). DCs were transfected with pBudCE4.1/SLC-IL-2 by gene electric transfection. Protein expression was determined with Western blot and enzyme-linked immunosorbent assays. Cytotoxicity of TC and DC against the human bladder tumor cell were examined by chromium release assay. Flow cytometric analyses were performed to determine the apoptosis of tumor cells and the percentage of Treg. Results: A high level of expression of SLC and IL-2 was observed in DCs transfected with SLC and IL-2 genes. The mean production of IL-2 was 19.8 ± 2.5, 511.10 ± 52.36, and 541.3 ± 62.04 ng/106 cells/24 hours in the DC/vector, DC/IL-2, and DC/SLC-IL-2, respectively. The mean SLC production was 29.8 ± 4.43, 506.10 ± 42.36, and 567.34 ± 52.05 ngs/10 6cells/24 hours in the DC/ vector, DC/SLC, and DC/SLC-IL-2, respectively. Cytotoxicity to bladder cancer cells was increased. The mean cytotoxicity (the effector/target ratio, 40:1) of TC-DC/parental, TC-DC/IL-2, TC-DC/SLC, and TC-DC/SLC-IL-2(TDSI) to the human bladder cancer cells was 32.1 ± 5.5, 63.5 ± 6.6, 78.1 ± 9.63, respectively. The apoptotsis rate of bladder cancer cells treated with TDSI was 18.6 by flow cytometry. Treg cells' percentage was very small in the DC medium. Conclusions: SLC and IL-2 were produced by autocrine in DCs transfected with SLC and IL-2 genes. DC/SLC-IL-2 can promote DC proliferation, while TC-DC/SLC-IL-2 and TC-DC/SLC could strongly enhance significant cytotoxicity against bladder cancer cell that was induced by the coculture of DCs (transfected with SLC and IL-2) and TC.
KW - Bladder and prostrate cancer
KW - Gene expression
KW - Therapy
KW - Tumor immunology
UR - http://www.scopus.com/inward/record.url?scp=70350180213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350180213&partnerID=8YFLogxK
U2 - 10.3109/07357900802375746
DO - 10.3109/07357900802375746
M3 - Article
C2 - 19832038
AN - SCOPUS:70350180213
SN - 0735-7907
VL - 27
SP - 909
EP - 917
JO - Cancer Investigation
JF - Cancer Investigation
IS - 9
ER -